Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model

Medical Journal of Indonesia

Volumn 19, Issue 1, 2010, Pages 5-13

  Murti, Krisna ^a   Butler, Lisa M ^b   Sakko, Andrew ^b   Ricciardelli, Carmela ^b   Mitto, Tina B ^b   Octnick, Alexandra ^b   Stahl, Jurgen ^c   Tilley, Wayne D ^b  

^a SRIWIJAYA UNIVERSITY   (Indonesia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Adelaide Spine Clinic   (Australia)

Author keywords

Androgen ablation therapy; Haematoxylin and eosin; Tissue microarrays; Video image analysis

Indexed keywords

ANDROGEN RECEPTOR;

ANDROGEN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CASTRATION; CONTROLLED STUDY; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HYPERPLASIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICROSCOPY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR MODEL;

EID: 85008951570     PISSN: 08531773     EISSN: 22528083     Source Type: Journal    
DOI: 10.13181/mji.v19i1.376     Document Type: Article

References (25)

1. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004; 91: 483-90.
2. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signalling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93:1687-97.
3. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. Prostate 2004; 58: 211-24.
4. Tilley WD, Buchanan G, Coetzee GA. Androgen receptor signalling in prostate cancer. In: Henderson BE, Ponders BA, Ross RK, editors. Hormones, genes, and cancer. New York: Oxford University; 2003.
5. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003; 10: 209-16.
6. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Leland WK, Chung LWK, et al. The Current state of preclinical prostate cancer animal models. Prostate. 2008; 68: 629-39.
7. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmaan MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res. 2004; 64: 2270-305.
8. Mobasheri A, Airley R, Foster CS, Tanzil GS, Shakibaei. Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clinical genomics and drug discovery. Histol Histopathol. 2004; 19: 325-35.
9. Mohler JL, Gregory CW, Ford III OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004; 10: 440-8.
10. Feldman BJ, Feldman D. The Development of androgen-independent prostate cancer. Nature Rev. 2001: 1; 34-45.
11. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Meta Rev. 2001; 20: 207–23.
12. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate. Am J Surg Pathol. 2004; 28: 928-34.
13. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, et al. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate. 2007: 67; 83-106.
14. Kaplan-Lefco PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003; 55: 219-37.
15. Wikstrom P, Lindahl C, Bergh A. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate. 2005; 62: 148-64.
16. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A. Androgen receptors in prostate cancer. J Urol. 2003; 170: 1363–69.
17. Segawa N, Nakamura M, Shan L, Utsunomiya H, Nakamura Y, Mori I, et al. Expression and somatic mutation on androgen receptor gene in prostate cancer. Int J Urol. 2002; 9: 545-53.
18. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. Am J Pharmaco Genom. 2001; 1: 241-9.
19. Gaston KE, Kim D, Singh S, Ford III OH, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003; 70: 990-3.
20. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate. 2005; 63: 19-28.
21. Henshall SM, Quinn DI, Lee SL, Head DR, Golovsky D, Brenner PC, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001; 61: 423-7.
22. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004; 11: 459-76.
23. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003; 107: 1-10.
24. Barclay WW, WoodruffRD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology. 2005; 146: 13-8.
25. Scher HI, Sawyer CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signalling axis. J Clin Oncol. 2005; 23: 8253-61.